| H. LUNDBECK A/S Patent applications |
| Patent application number | Title | Published |
|---|
| 20120135987 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS - This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. | 05-31-2012 |
| 20120129836 | Imidazole derivatives as PDE10A enzyme inhibitors - This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. | 05-24-2012 |
| 20120123123 | PREPARATION OF NALMEFENE HYDROCHLORIDE FROM NALTREXONE - Method for producing nalmefene hydrochloride from naltrexone, which method is particular well adapted for large-scale industrial application, and has been found to be efficient, to give a high yield and to afford highly pure nalmefene hydrochloride salt. | 05-17-2012 |
| 20120116085 | METHOD FOR THE MANUFACTURING OF NALTREXONE - The present invention relates to an improved process for producing naltrexone[17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxy-morphinan-6-one] from noroxymorphone[4,5-α-epoxy-3,14-dihydroxy-morphinan-6-one] by alkylation with a cyclopropylmethyl halide. | 05-10-2012 |
| 20120082671 | MODULATION OF ACTIVITY OF NEUROTROPHINS - The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. | 04-05-2012 |
| 20120077836 | METHODS OF ADMINISTERING (4AR,10AR)-1-N-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO [G] QUINOLINE-6,7-DIOL AND RELATED COMPOUNDS ACROSS THE ORAL MUCOSA, THE NASAL MUCOSA OR THE SKIN AND PHARMACEUTICAL COMPOSITIONS THEREOF - Disclosed are pharmaceutical compositions and methods for the administration of (4aR,10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol or a pharmaceutically acceptable salt thereof and related compounds for the treatment of neurological disorder such as Parkinson's disease and restless leg syndrome. | 03-29-2012 |
| 20120035188 | LIQUID FORMULATIONS OF SALTS OF 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)PHENYL]-PIPERAZINE - Liquid formulations of lactic acid addition salts of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine are provided. | 02-09-2012 |
| 20120004409 | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine - The present invention concerns a process for the manufacture of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine. | 01-05-2012 |
| 20110301190 | POLYMORPHIC FORMS OF A GABAA AGONIST - The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms. | 12-08-2011 |
| 20110294787 | SUBSTITUTED THIOMORPHOLINE DERIVATIVES - The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use. | 12-01-2011 |
| 20110288120 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS - Isoquinolone derivatives of the general formula (I) are NK3 antagonists. | 11-24-2011 |
| 20110251228 | NALMEFENE HYDROCHLORIDE DIHYDRATE - The present invention relates to the Nalmefene hydrochloride dihydrate, methods of manufacturing Nalmefene hydrochloride dihydrate, a pharmaceutical composition comprising Nalmefene hydrochloride dihydrate and a method of treatment comprising administering Nalmefene hydrochloride dehydrate. | 10-13-2011 |
| 20110230497 | BIOLOGICALLY ACTIVE AMIDES - The present invention is directed to biologically active amides which are ligands at the NPY Y5 receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from certain disorders which comprises administering to the subject an amount of a compound of the subject invention. Furthermore, this invention also provides uses of a compound of the invention for the manufacture of a medicament for treating a subject suffering from certain disorders. | 09-22-2011 |
| 20110224247 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS - The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds. | 09-15-2011 |
| 20110207744 | Method for treating cognitive deficits - The invention relates to methods of treating cognitive dysfunction and improving cognitive functioning comprising the administration of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine or a pharmaceutically acceptable salt thereof to a patient in need thereof. Moreover the invention relates to an improved binder in a composition comprising 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine. | 08-25-2011 |
| 20110201617 | Therapeutic Uses Of Compounds Having Combined SERT, 5-HT3 And 5-HT1A Activity - New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided. | 08-18-2011 |
| 20110178094 | Oral Formulation - The invention relates to a pharmaceutical composition intended for oral administration comprising low doses of 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and to a composition comprising the compound. | 07-21-2011 |
| 20110178086 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME - The present invention provides adamantyl-diamide derivatives of formula (I): | 07-21-2011 |
| 20110166036 | MODULATION OF THE VPS10P-DOMAIN FOR THE TREATMENT OF CARDIOVASCULAR DISEASE - The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of abnormal plasma lipid concentrations and associated diseases and/or disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention furthermore relates to methods of altering expression of said receptors in vivo. | 07-07-2011 |
| 20110166032 | Design and Use of Sortilin Specific Molecular Imaging Ligands - The present invention provides methods for design and identification of Vps10p domain receptor specific molecular imaging ligands based on the atomic coordinates of said Vps10p-domain. The present invention also relates to the preparation and use of such ligands for the preparation of a target specific imaging reagent or molecular imaging probe useful in detection of said Vps10p-domain receptor involved in disease. | 07-07-2011 |
| 20110160439 | Design of specific ligands to sortilin - The present invention provides a Sortilin crystal and methods for growing said crystal. The invention furthermore provide methods for design of specific ligands based on the crystal structure of Sortilin. The present invention also relates to the preparation and use of such ligands for the preparation of a medicament for the treatment of disease, damage or disorders of the central and peripheral nervous systems. | 06-30-2011 |
| 20110152539 | PROCESSES FOR THE MANUFACTURE OF A PHARMACEUTICALLY ACTIVE AGENT - Disclosed herein are processes for the preparation of a pharmaceutically active agent and pharmaceutically acceptable salts thereof. | 06-23-2011 |
| 20110144164 | Pyridone derivatives as NK3 antagonists - The present invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds. | 06-16-2011 |
| 20110142830 | MODULATION OF THE TRPV: VPS10P RECEPTOR SYSTEM FOR THE TREATMENT OF PAIN - This invention relates to the use of an agent capable of binding and thus inhibit formation of a binary Vps10p-domain receptor:TrpV receptor complex, and/or formation of a further ternary Vps10p-domain receptor:TrkA:TrpV receptor complex for the preparation of a medicament for the inhibition of pain and pain signalling through said complex(es). The invention is thus beneficial in the preparation of a medicament for the treatment and/or prevention of neuropathic pain, chronic pain and acute pain. The invention furthermore relates to the identification of such agents and animal models for screening for such agents. | 06-16-2011 |
| 20110130407 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS - Isoquinolone derivatives of the general formula I are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia. | 06-02-2011 |
| 20110104165 | METHOD OF UPREGULATING SORLA FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The present invention is directed to use of an agent capable of upregulating the Vps10p-domain receptor SorLA. In particular, the present invention relates to use of CTGF and/or BDNF and/or fragments and/or variants thereof for the inhibition of plaque formation thereby being useful in the treatment of Alzheimer's Disease or other disorders associated with elevated of amyloid beta or amyloid plaque. | 05-05-2011 |
| 20110098299 | SPIROLACTAM DERIVATIVES AND USES OF SAME - The present invention provides spirolactam derivatives of formula (I): | 04-28-2011 |
| 20110098286 | (3-ARYL-PIPERAZIN-1-YL), (2-ARYL-MORPHOLIN-4-YL) AND (2-ARYL-THIOMORPHOLIN-4-YL) DERIVATIVES OF 6,7-DIALKOXY-QUINAZOLINE, 6,7-DIALKOXYPHTALAZINE AND 6,7-DIALKOXYISOQUINOLINE - This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides a process for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. | 04-28-2011 |
| 20110092475 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME - The present invention provides 2-substituted-ethynylthiazole derivatives of formula (I): | 04-21-2011 |
| 20110065938 | METHOD FOR THE PREPARATION OF ESCITALOPRAM - A novel method is provided for the manufacture of escitalopram. The method comprises chromatographic separation of the enantiomers of citalopram or an intermediate in the production of citalopram using a chiral stationary phase such as Chiralpak™ AD or Chiralcel™ OD. Novel chiral intermediates for the synthesis of Escitalopram made by said method are also provided. | 03-17-2011 |
| 20110065937 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM - The present invention relates to a novel method for the preparation of diol intermediates having the formula (II) and/or the opposite enantiomer of an acylated diol having the formula (IV) useful for the preparation of escitalopram involving selective enzymatic acylation or deacylation. | 03-17-2011 |
| 20110054178 | PROCESS FOR THE MANUFACTURE OF [PHENYLSULFANYLPHENYL]PIPERIDINES - A process for the manufacture of (un)substituted phenylsulfanylphenyl-piperidines comprising the use of benzyl as N-piperidine protecting group is disclosed. | 03-03-2011 |
| 20110053978 | THERAPEUTIC USES OF COMPOUNDS HAVING AFFINITY TO THE SEROTONIN TRANSPORTER, SEROTONIN RECEPTORS AND NORADRENALIN TRANSPORTER - Therapeutic uses of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine and therapeutically acceptable salts thereof are provided. | 03-03-2011 |
| 20110053957 | MALONATE SALT OF 4-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND USES OF SAME - 4-((1R,35)-6-Chloro-3 -phenylindan-1-yl)-1,2,2-trimethylpiperazine hydrogen malonate salt and pharmaceutical comprising and uses of the same, including for the treatment of schizophrenia and other psychotic disorders are described. | 03-03-2011 |
| 20110046218 | CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE - The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet. | 02-24-2011 |
| 20110039890 | 4-[2,3-Difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine - The compound 4-[2,3-Difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine according to the structure (formula I), and pharmaceutically acceptable salts thereof are provided for the treatment of CNS related disorders, such as: depressive disorder, dysthymic disorder; mood disorder due to a general medical condition; atypical depression; seasonal affective disorder; melancholia; treatment resistant depression; partial responders; depression associated with bipolar disorder, pain, Alzheimer's disease, psychosis, Parkinson's disease, Lewy body disease, Huntington's disease, multiple sclerosis or anxiety; general anxiety disorder, social anxiety disorder, panic attacks; phobia; social phobia, obsessive compulsive disorder; post traumatic stress disorder, acute stress; ADHD; and pain. | 02-17-2011 |
| 20110009423 | PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS - The invention provides compounds represented by the general formula I | 01-13-2011 |
| 20110009422 | 1- [2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF PAIN OR RESIDUAL SYMPTOMS IN DEPRESSION RELATING TO SLEEP AND COGNITION - The use of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine in the treatment of pain and residual symptoms in depression is provided. | 01-13-2011 |
| 20110003811 | SUBSITUTED PYRIDINE DERIVATIVES - The present invention relates to pyridine derivatives of the general formula (I) and their use as openers of the KCNQ family potassium ion channels for the treatment of CNS disorders. | 01-06-2011 |
| 20100324291 | PROCESSES FOR 4-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE OR A SALT THEREOF - Methods for the preparation of 4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and salts thereof are described. | 12-23-2010 |
| 20100297240 | 1- [2- (2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT - 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT | 11-25-2010 |
| 20100292236 | 5-Membered Heterocyclic Amides And Related Compounds - 5-Membered heterocyclic amides and related compounds are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies. | 11-18-2010 |
| 20100286226 | COMBINATION THERAPY RELATED TO SEROTONIN DUAL ACTION COMPOUNDS - The present invention relates to combination therapies and pharmaceutical compositions comprising a combination of 5-hydroxytryptophan and a serotonin reuptake inhibitor that binds to an ailosteric site of the serotonin transporter. The present invention further provides a pharmaceutical composition comprising (i) 5-hydroxytryptophan in an amount ranging from about 1 mg to about 75 mg; and (ii) a serotonin reuptake inhibitor that binds to an allosteric site of the serotonin transporter. | 11-11-2010 |
| 20100286138 | Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide - Polymorphic forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide are provided together with a process for the manufacture of said compound. | 11-11-2010 |
| 20100216763 | Heteroaryl Amide Derivatives - Heteroaryl amide derivatives are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies. | 08-26-2010 |
| 20100144788 | 4- [2- (4-METHYLPHENYLSULFANYD-PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF ADHD, MELANCHOLIA, TREATMENT RESISTENT DEPRESSION OR RESIDUAL SYMPTOMS IN DEPRESSION - The use of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine and acid additions salts thereof for the treatment of ADHD, melancholia, treatment resistant depression or residual symptoms in depression is provided. | 06-10-2010 |
| 20100137366 | 4- [2- (4-METHYLPHENYLSULFANYL) PHENYL] PIPERIDINE FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME (IBS) - The use of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine or a pharmaceutically acceptable salt thereof in the treatment of irritable bowl syndrome. | 06-03-2010 |
| 20100137311 | SUBSTITUTED PYRIMIDINE DERIVATIVES - The present invention relates to pyrimidine derivatives of the general formula I or salts thereof | 06-03-2010 |
| 20100105730 | LIQUID FORMULATIONS OF SALTS OF 4-[2-(4-METHYLPHENYLSULFANYL)PHENYL]PIPERIDINE - Liquid formulations of the DL-lactic acid, the glutaric acid, the L-aspartic acid and the glutamic acid salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine and their use in the manufacture of a medicament to be used in the treatment of CNS diseases are provided. | 04-29-2010 |
| 20100105699 | CRYSTALLINE BASE OF TRANS-1-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-3,3-DIMETHYLPIPERAZINE - Crystalline base of compound trans-1-(1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine, processes for the preparation of purified free base or salts of this compound, pharmaceutical compositions comprising the base and medical use thereof, including for treatment of schizophrenia and other psychotic disorders. | 04-29-2010 |
| 20100093787 | TREATMENT OF IMPAIRED RESPIRATORY FUNCTION WITH GABOXADOL - The present invention relates to a method for treating impaired respiratory function in a human patient suffering from sleep apnea, such as central sleep apnea or obstructive sleep apnea, comprising administering to said patient an effective amount of gaboxadol per day. | 04-15-2010 |
| 20100076016 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS - The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds. | 03-25-2010 |
| 20100069676 | PROCESS FOR MAKING TRANS-1-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-3,3-DIMETHYLPIPERAZINE - Described is a method for making the trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine (formula I) and salts thereof and a similar method for making 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine (formula IX) and salts thereof, which method comprises conversion of a compound of formula IVa to the compound of formula I or the compound of formula IX, respectively. | 03-18-2010 |
| 20100063044 | SUBSTITUTED ANILINE DERIVATIVES - The present invention relates to aniline derivatives of formula I: | 03-11-2010 |
| 20100063036 | Substituted morpholine and thiomorpholine derivatives - The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use. | 03-11-2010 |
| 20100022546 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME - The present invention provides adamantyl-diamide derivatives of formula (1): | 01-28-2010 |
| 20100016303 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS - This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. | 01-21-2010 |
| 20090326036 | [2-(6-FLUORO-1H-INDOL-3-YLSULFANYL)BENZYL]METHYL AMINE FOR THE TREATMENT OF AFFECTIVE DISORDERS - [2-(6-fluoro-1H-indol-3-ylsulfanyl)benzyl]methyl amine and pharmaceutically acceptable salts thereof, provided it is not the free base in a non-crystalline form are provided for the treatment of affective disorders. | 12-31-2009 |
| 20090325946 | NOVEL PHENOLIC AND CATECHOLIC AMINES AND PRODRUGS THEREOF - The present invention relates to novel phenolic and catecholic amines of Formula I, to processes for their preparation, pharmaceutical compositions containing them, to their use in therapy and to their use in radiolabeled form as PET- or SPECT ligands. | 12-31-2009 |
| 20090306092 | METHOD FOR TREATING COGNITIVE DEFICITS - The invention relates to methods of treating cognitive dysfunction and improving cognitive functioning comprising the administration of trans-4-((1R,3S)-6-chloro-3-phenylindan- | 12-10-2009 |
| 20090270453 | ANTI-MANIC EFFECTIVE DOSES OF SERTINDOLE - The present invention relates to uses of an anti-manic effective dose sertindole in the preparation of a pharmaceutical composition for the treatment of mania, and to methods of treating mania comprising administering said effective dose of sertindole. In separate aspects of the invention, said uses and methods are directed to treating manic episodes. | 10-29-2009 |
| 20090264656 | METHOD FOR MANUFACTURE OF SERTINDOLE - The present invention relates to a novel method for manufacture of sertindole comprising manufacturing 5-chloro-1-(4-fluorophenyl)-indole and converting it to sertindole wherein the method for manufacture of 5-chloro-1-(4-fluorophenyl)-indole comprises reacting 5-chloro-indole with a 4-fluorophenylhalide in the presence of a base, a chelating ligand and catalytic amounts or a copper salt comprising copper(I) or copper(II) and an anion which does not interfere in an unfavourable way with the reaction. | 10-22-2009 |
| 20090264465 | CRYSTALLINE FORMS OF 4- [2- (4-METHYLPHENYLSULFANYL) -PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF NEUROPATHIC PAIN - Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine and salts thereof are provided e.g. for the treatment of neuropathic pain. | 10-22-2009 |
| 20090247772 | Method for the Preparation of Escitalopram - The invention relates to intermediates and the use thereof in a method for the preparation of escitalopram: | 10-01-2009 |
| 20090247593 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES - The invention relates to compounds of the formula I | 10-01-2009 |
| 20090215774 | USES OF INDANE COMPOUNDS - The invention provides methods of treating obesity and eating disorders, which comprise administering indane compounds of Formula (I): | 08-27-2009 |
| 20090203731 | TREATMENT OF DEPRESSION AND OTHER AFFECTIVE DISORDERS - The present invention relates to use of gaboxadol for preparing a pharmaceutical composition for treating depression. Moreover, it relates to the use of gaboxadol for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin. | 08-13-2009 |
| 20090203721 | USE OF SIRAMESINE IN THE TREATMENT OF CANCER - The present invention relates to the treatment of cancer. In particular, the invention provides pharmaceutical compositions comprising siramesine for the treatment of cancer. The invention further provides a method of treatment comprising administering siramesine to a patient suffering from cancer. | 08-13-2009 |
| 20090192213 | Benzo[b]furane And Benzo[b]thiophene Derivatives - The present invention relates to benzo[b]furane and benzo[b]thiophene derivatives of the general formula IV as the free base or salts thereof and their use. | 07-30-2009 |
| 20090176808 | COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A 5-HT2C ANTAGONIST, INVERSE AGONIST OR PARTIAL AGONIST - The present invention relates to the use of compounds and compositions of compounds having serotonin reuptake inhibiting activity and 5-HT | 07-09-2009 |
| 20090143435 | GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity - The invention provides the use of a non-steroid compound which acts on the GABA receptor for the treatment of disorders relating to reduced neurosteroid activity. The non-steroid compounds may be GABA agonists, GABA uptake inhibitors or enhancers of GABAergic activity. | 06-04-2009 |
| 20090143402 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS - Isoquinolone derivatives of the general formula | 06-04-2009 |
| 20090143369 | METHODS OF USING SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES - The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use. | 06-04-2009 |
| 20090143335 | MODIFIED ABSORPTION FORMULATION OF GABOXADOL - The present invention relates to a pharmaceutical composition comprising gaboxadol or a pharmaceutically acceptable salt thereof and one or more inhibitors of PAT1 and/or one or more inhibitors of OAT. The present invention further relates to a pharmaceutical composition comprising from about 0.5 mg to about 50 mg gaboxadol or a pharmaceutically acceptable salt thereof, wherein the composition provides an in vivo plasma profile comprising a mean Tmax which is longer than about 20 minutes. | 06-04-2009 |
| 20090137642 | 2-Acylaminothiazole Derivatives - The Invention relates to compounds of the formula I, wherein the variables are as defined in the claims, for use as a medicament. The compounds are A | 05-28-2009 |
| 20090137571 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES - The present invention relates to morpholine and thiomorpholine derivatives or the general formula I or pharmaceutically acceptable salts thereof and their use. | 05-28-2009 |
| 20090136519 | Tissue Protective Cytokine Receptor Complex, Assays for Identifying Tissue Protective Compounds and Uses Thereof - The present invention is directed methods for identifying compounds that have a tissue protective activity using a heteromultimer receptor complex that mediates the tissue protective activities. The complex consists of at least one EPO-R in complex with at least one βc Receptor. These compounds used in the assays to identify tissue protective compounds include, but are not limited to, small molecules and biologics. The compounds identified using these assays can be used to treat or prevent various diseases, disorders, or conditions of the central and peripheral nervous systems as well as those of other erythropoietin-responsive or excitable cells, tissues, and organs. | 05-28-2009 |
| 20090125331 | METHODS AND SYSTEMS FOR TREATING ILLNESSES - The present invention provides systems comprising two main components—a static and a dynamic component—that coupled with at least one interactive element of the systems permit providing information and support to a patient having a disease or disorder, responding to potential treatment issues of the patient, tracking a patient's treatment, and thereby improving patient compliance; as well as methods of using the systems, including methods of treating the patient and of ensuring the authenticity of a medication used by the patient. | 05-14-2009 |
| 20090124651 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF - The present invention relates to novel catecholamine derivatives of Formula I, to processes for their preparation, pharmaceutical compositions containing them and to their use in therapy. | 05-14-2009 |
| 20090118285 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA - The invention relates to a novel method for treating or reducing the symptoms of schizophrenia, said method comprising administering to a host in need thereof an effective amount of a compound able to selectively increase the ion flow through KCNQ potassium channels. Furthermore the invention relates to the use of selective KCNQ potassium channel openers for the preparation of a pharmaceutical composition for treating or reducing the symptoms of schizophrenia and related symptoms, disorders and diseases. Furthermore the invention relates to a method of screening for a compound, which is a selective KCNQ potassium channel opener and which is capable of having an anti-psychotic potential. | 05-07-2009 |
| 20090088469 | METHOD FOR THE PREPARATION OF CITALOPRAM - Method for the preparation of citalopram comprising reaction of a compound of Formula (IV) wherein R is halogen, or CF | 04-02-2009 |
| 20090075988 | CYANOISOQUINOLINE - This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides a process for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. | 03-19-2009 |
| 20090069582 | METHOD FOR MANUFACTURE OF ESCITALOPRAM - This patent discloses a method for resolution of 4-[4-(dimethylamino)-1-(4′-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile as a racemic or non-racemic enantiomer mixture into its isolated enantiomers, said method comprising the step of fractionally crystallizing 4-[4-(dimethylamino)-1-(4′-fluoro-phenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile as a salt with the (+)—(S,S)— or (−)—(R,R)-enantiomer of O,O′-di-p-toluoyl-tartaric acid in a solvent system comprising 1-propanol, ethanol or acetonitrile. | 03-12-2009 |
| 20090062324 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF - The present invention relates to novel catecholamine derivatives of Formula I, to processes for their preparation, pharmaceutical compositions containing them and to their use in therapy. | 03-05-2009 |
| 20090054510 | METHOD FOR IDENTIFYING COMPOUNDS FOR THE TREATMENT OF DEPRESSION - An assay for identifying compounds with increased efficacy in the treatment of depression is disclosed. The assay comprises the steps of determining whether a test compound inhibits SERT and whether it inhibits with an allosteric site ion SERT. | 02-26-2009 |
| 20090048288 | METHOD OF TREATING STRESS-MEDIATED DEPRESSION - The present invention relates to a method for the treatment of depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers in said patient is increased or abnormal. The present invention also relates to a method for the treatment of stress-mediated depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers is increased or abnormal in said patient. The present invention also relates to a method for the treatment of depression or the amelioration of one or more depressive symptoms comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the clinical presentation of one or more symptoms of depression are the physiological effect of a general medical condition. Furthermore the present also relates to a method for testing the therapeutic effectiveness of a compound in the treatment of depression or reducing the symptoms of depression comprising measuring the amount of one or more inflammatory markers in a sample from a patient before said compound is administered to the patient and comparing with the amount of said one or more inflammatory markers in a sample from the same patient after administration of said compound to the patient. | 02-19-2009 |
| 20080318953 | Substituted Pyridine Derivatives - The present invention relates to pyridine derivatives of the general formula (I) and their use as openers of the KCNQ family potassium ion channels for the treatment of CNS disorders. | 12-25-2008 |
| 20080305164 | CRYSTALLINE COMPOSITION CONTAINING ESCITALOPRAM - Crystalline particles of escitalopram oxalate with a particle size of at least 40 μm is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed. | 12-11-2008 |
| 20080269278 | Treatment of Impaired Respiratory Function with Gaboxadol - The present invention relates to a method for treating impaired respiratory function in a human patient suffering from sleep apnea, such as central sleep apnea or obstructive sleep apnea, comprising administering to said patient an effective amount of gaboxadol per day. | 10-30-2008 |
| 20080269248 | Tartrate and Malate Salts of Trans-1-((1R,3S)-6-Chloro-3-Phenylindan-1-Yl)-3,3-Dimethylpiperazine - A tartrate and malate salt of trans-1-(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine, in particular for medical use, pharmaceutical formulations thereof, including for treatment of schizophrenia or other diseases involving psychotic symptoms. | 10-30-2008 |
| 20080262029 | Acid and Base Salt Forms of Gaboxadol - The present invention is directed to novel acid salt forms and base salt forms of the compound gabaoxadol (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol) and hydrates, solvates and polymorphic forms thereof. The invention is further concerned with pharmaceutical compositions containing the salt forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the salt forms, and processes for the preparation of the salt forms. | 10-23-2008 |
| 20080214645 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS - The present invention relates to uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives of general formula (I): | 09-04-2008 |
| 20080214644 | 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRI - The present invention relates to 2-(1H-indolylsulfanyl)-benzyl amine derivatives of general formula (I): | 09-04-2008 |
